GlassScriptPhysician profile
Kimberly M Quick
NPI 1851342885
$3,595.85
in general payments reported to CMS, 2019-2025
30 companies · $864 in 2025
The $864 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,097 · 2020: $286 · 2021: $231 · 2022: $250 · 2023: $293 · 2024: $576 · 2025: $864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,725 · Education: $6.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,725.47 |
| Education | $6.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $466.46 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $437.07 | 2019-2024 | Xarelto |
| Pfizer INC. | $416.51 | 2019-2025 | |
| Amgen INC. | $356.68 | 2019-2025 | Repatha, Repatha |
| Abbott Laboratories | $227.79 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $199.93 | 2024-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $168.37 | 2019-2024 | Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $162.99 | 2019-2023 | Lifevest |
| Regeneron Healthcare Solutions, INC. | $140.91 | 2019 | |
| Alnylam Pharmaceuticals INC. | $118.08 | 2024-2025 | Onpattro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.35 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $93.29 | 2024-2025 | Wegovy, Ozempic |
| Lundbeck LLC | $92.53 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $74.56 | 2021-2025 | Verquvo, Capvaxive |
| Scpharmaceuticals INC. | $71.85 | 2024-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $62.98 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $62.00 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $45.34 | 2023-2024 | Opsumit, Uptravi |
| Kowa Pharmaceuticals America, INC. | $45.31 | 2019-2020 | |
| Kiniksa Pharmaceuticals, LTD. | $34.00 | 2023 | Arcalyst |
| Kestra Medical Technology Services, INC. | $29.48 | 2023 | Assure Wcd |
| Lexicon Pharmaceuticals, INC. | $27.82 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.41 | 2025 | |
| Astellas Pharma US INC | $24.23 | 2019 | |
| Nuwellis, INC. | $23.96 | 2019 | |
| Boston Scientific Corporation | $17.67 | 2020 | |
| Ethicon US, LLC | $15.29 | 2024 | Vistaseal |
| Medtronic Vascular, INC. | $15.16 | 2019 | |
| Chiesi USA, INC. | $12.52 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Quick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.